On Wednesday, Shares of Masco Corp (NYSE:MAS), lost -0.82% to $30.17.
Masco Corporation, declared that Chief Financial Officer John Sznewajs will present at the Bank of America Merrill Lynch 2015 Paper, Packaging and Builders Conference on December 9 in Boston at 8:00 a.m. ET.
Masco Corporation manufactures, distributes, and installs home improvement and building products worldwide. Its Cabinets and Related Products segment provides cabinetry for kitchen, bath, storage, home office, and home entertainment applications; and kitchen countertops, and integrated bathroom vanity and countertop solutions.
Shares of Southern Co (NYSE:SO), declined -2.15% to $44.21, during its last trading session.
Southern Company partner Southern Power recently declared the acquisition of a controlling interest in the 157-megawatt (MW) Roserock solar facility – the company’s first solar project in Texas – from Recurrent Energy, one of North America’s largest solar developers. The latest addition to one of America’s largest renewable portfolios, the facility is being developed by Recurrent Energy, a partner of Canadian Solar Inc., which will retain the remaining interest in the project.
“Southern Power’s first solar project in Texas assists further the company’s robust wholesale business and further expands our solar footprint,” said Southern Power President and CEO Oscar C. Harper. “With planned acquisitions nationally, the continued development of industry-leading assets aligns with our company’s low-risk strategy and enhances one of America’s largest renewable portfolios.”
Representing Southern Power and Recurrent Energy’s second partnership arrangement, the project, presently under construction, is predictable to enter commercial operation in the fourth quarter of 2016.
The Southern Company, together with its auxiliaries, operates as a public electric utility company. It is involved in the generation, transmission, and distribution of electricity through coal, nuclear, oil and gas, and hydro resources in the states of Alabama, Georgia, Florida, and Mississippi.
Finally, Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), ended its last trade with 1.33% gain, and closed at $2.29.
Eisai Inc. and Arena Pharmaceuticals, declared that the CAMELLIA-TIMI 61 study has reached its target enrollment of 12,000 patients at more than 470 sites in eight countries. The CAMELLIA-TIMI 61 outcomes study is designed to evaluate the impact of long-term treatment with BELVIQ® (lorcaserin HCl) CIV on the incidence of major adverse cardiovascular events and conversion to type 2 diabetes mellitus in obese and overweight patients with cardiovascular disease and/or multiple cardiovascular risk factors.
“We are happy to see full enrollment in this important study, which will advance scientific understanding of the long-term safety and efficacy of BELVIQ in overweight and obese patients,” said Andrew Satlin, MD, Executive Vice President, Neuroscience and General Medicine PCU, Eisai Inc. “As a company focused on human health care, we are committed to increasing our knowledge of the effects of BELVIQ on cardiovascular health.”
The five-year study, conducted in partnership with the Thrombolysis in Myocardial Infarction (TIMI) Study Group, will address the post-marketing requirement from the U.S. Food and Drug Administration to evaluate the long-term cardiovascular safety of BELVIQ. In addition, the study comprises two primary efficacy endpoints: (1) to assess the effect of BELVIQ on cardiovascular event risk reduction and (2) to assess the effect of BELVIQ on the conversion to type 2 diabetes mellitus among patients without diabetes at baseline.
“We are very excited that CAMELLIA-TIMI 61 has accomplished enrollment in such a timely fashion,” said Benjamin M. Scirica, MD, MPH, Senior Investigator, TIMI Study Group and Associate Professor of Medicine, Harvard Medical School and Co-Primary Investigator of the CAMELLIA-TIMI 61 Trial. “The enthusiasm and speed of enrollment highlights the commitment to evaluate the efficacy and safety of pharmacotherapy in obese and overweight patients who have cardiovascular disease or are at risk of cardiovascular complications. As the largest ongoing outcomes trial in obesity, CAMELLIA-TIMI 61 will provide invaluable information about this traditionally difficult to treat population.”
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight administration in adults.